

Possible repositioning of an oral anti-osteoporotic drug, Ipriflavone, for treatment of inflammatory arthritis via inhibitory activity of KIAA1199, a novel potent hyaluronidase.

Hiroshi Koike¹, Yoshihiro Nishida², Tamayuki Shinomura³, Bisei Ohkawara⁴, Kinji Ohno⁴, Lisheng Zhuo¹, Koji Kimata⁵, Takahiro Ushida⁵, Shiro Imagama¹

¹Department of Orthopedic Surgery, Nagoya University Graduate School of Medicine, 65 Tsurumai, Showa, Nagoya, Aichi, 466-8550, Japan

²Department of Rehabilitation Medicine, Nagoya University Hospital, 65 Tsurumai, Showa, Nagoya, Aichi, 466-8550, Japan

³Department of Hard Tissue Engineering, Tokyo Medical and Dental University, Tokyo, 113-8510, Japan

⁴Division of Neurogenetics, Center for Neurological Diseases and Cancer, Nagoya University Graduate School of Medicine, 65 Tsurumai, Showa, Nagoya, Aichi, 466-8550, Japan

⁵Multidisciplinary Pain Center, Aichi Medical University, Nagakute, Aichi, 480-1195, Japan

* Correspondence: Correspondence and reprint requests to Y. Nishida, Department of Rehabilitation Medicine, Nagoya University Hospital, 65 Tsurumai, Showa, Nagoya, Aichi, 466-8550, Japan
Phone: 81-52-741-2111, Fax: 81-52-744-2260, E-mail: ynishida@med.nagoya-u.ac.jp




Figure S1. Relative mRNA expression of KIAA1199 in RCS cells. RCS-KIAA represents RCS cells, which are transfected with mouse KIAA1199 cDNA.




Figure S2. Representative image of RCS with Alcian blue staining RCS cells (A) and RCS-KIAA cells (B) were mono-cultured for 24 h and stained with Alcian blue. Bar = 20 μ m.




Figure S3. Schematic diagram of the experimental protocol for the CIA mouse model.